

REMARKS

The Examiner has requested clarification of the elected substrate "SEAP/6H/Spi/TGF $\alpha$ ", stating that the identity of the elected substrate remains undefined.

In particular, the Examiner indicated that the identities of "Spi" and "TGF $\alpha$ " were unclear. "Spi" refers to sequence from Drosophila Spitz. In the construct "SEAP/6H/Spi/TGF $\alpha$ ", the Spi sequence consists of residues 142-164 of Drosophila Spitz. This sequence is shown in bold below, and is shown in grey in construct (d) of figure 1 (attached to the C terminus of the MRGS(H)<sub>6</sub> tag sequence of SEQ ID NO:1).

Spitz (SEQ ID NO:16)  
ACCESSION Q01083  
VERSION Q01083.2 GI:50403762

```
1 MHSTMSVQHG LVALVLIGCL AHPWHVEACS SRTVPKPRSS ISSSMSGTAL PPTQAPVTSS
61 TTMRTTTTT PRPNITFPTY KCPETFDawy CLNDAHCFAV KIADLPVYSC ECAIGFMGQR
121 CEYKEIDNTY LPKRPRPMLE KASIASGAMC ALVFMLFVCL AFYLRFEQRA AKKAYELEQE
181 LQQEYDDDDG QCECCRNRCC PDGQEPIVILE RKL PYHMRLE HALMSFAIRR SNKL
```

The sequence of Drosophila Spitz is referenced in Table 2 by the database accession number Q01083 and the GI number 50403762. This sequence has been incorporated into the sequence listing as SEQ ID NO: 16. The "Spi" sequence of the elected substrate SEAP/6H/Spi/TGF $\alpha$  therefore consists of residues 142-164 of SEQ ID NO: 16.

"TGF $\alpha$ " refers to sequence from Human TGF $\alpha$ . In the construct "SEAP/6H/Spi/TGF $\alpha$ ", the TGF $\alpha$  sequence consists of residues 122-160 of Human TGF $\alpha$ . This sequence lacks the N terminal domain and TMD sequence and is shown in bold in the sequence below, and labelled as "TGF $\alpha$ C-term" in construct (d) of figure 1.

The sequence of Human TGF $\alpha$  is referenced in Table 2 by the database accession number P01135 and the GI number 135689. This sequence has been incorporated into the sequence listing as SEQ ID NO: 17. The "TGF $\alpha$ " sequence of elected substrate SEAP/6H/Spi/TGF $\alpha$  therefore consists of residues 122-160 of SEQ ID NO: 17 ("TGF $\alpha$ ").

Transforming growth factor alpha (SEQ ID NO:17)  
ACCESSION P01135  
VERSION P01135.1 GI:135689

1 MVPSAGQLAL FALGIVLAAQ QALENSTSPL SADPPVAAAV VSHFNDPDS HTQFCFHGTC  
61 RFLVQEDKPA CVCHSGYVGA RCEHADLLAV VAASQKKQAI TALVVVSIVA LAVLIITCVL  
121 **IHCQCVRKHC EWCRALICRH EKPSALLKGR TACCHSETVV**

**Certification Regarding Sequence Listing**

I hereby certify that the enclosed Sequence Listing is being submitted under 37 CFR §§ 1.821(c) and (e) in paper and computer readable form.

As required by 37 CFR 1.821(f), I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same.

I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

Atty Dkt. No.: MEWE-027  
USSN: 10/597,140


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number MEWE-027.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: January 12, 2010

By:

  
Pamela J. Sherwood, Ph.D.  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231